Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas

Clavreul, Anne; Piard, N.; Tanguy, Jean‐Yves; Gamelin, Eric; Rousselet, Marie‐Christine; Leynia, Pierre; Menei, Philippe

doi:10.1016/j.jocn.2009.11.017

Cited by 25 publications

(21 citation statements)

References 34 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of this, many cancer treatments use "whole-cell" vaccines prepared from resected tissue that contains the entire antigen spectrum for each patient's primary tumor (35)(36)(37). By enabling the immune system to react with unique epitopes, these vaccines can evoke reactions against an array of antigens that do not need to be preidentified by the physician.…”

Section: Discussionmentioning

confidence: 99%

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Smith

Moffett

Stephan

et al. 2017

Journal of Clinical Investigation

266

243

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Smith

Moffett

Stephan

et al. 2017

Journal of Clinical Investigation

266

243

View full text Add to dashboard Cite

“…Versions of GM-CSF secreting tumor cell vaccines have been employed for GBM (37, 38), often revealing technical difficulties (38). Current generations are accompanied by an allogeneic tumor cell line (K-562) secreting GM-CSF.…”

Section: Clinical Applications: Immunotherapeutic Approaches To Gbmmentioning

confidence: 99%

Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege

Fecci

Heimberger

Sampson

2014

Clinical Cancer Research

102

106

View full text Add to dashboard Cite

Immunotherapy for cancer continues to gain both momentum and legitimacy as a rational mode of therapy and a vital treatment component in the emerging era of personalized medicine. Gliomas, and their most malignant form, glioblastoma, remain as a particularly devastating solid tumor whose standard treatment options proffer only modest efficacy and target specificity. Immunotherapy would seem a well-suited choice to address such deficiencies given both the modest inherent immunogenicity of gliomas and the strong desire for treatment specificity within the confines of the toxicity-averse normal brain. This review highlights the caveats and challenges to immunotherapy for primary brain tumors, as well as reviews modalities that have been currently employed or are undergoing active investigation. Tumor immunosuppressive counter measures, peculiarities of CNS immune access, and opportunities for rational treatment design are discussed.

show abstract

“…Patients have be given individual peptides 52–54 , whole tumor lysate 55 , or some combination of tumor antigens and cytokines 56 .…”

Section: Clinical Reports Of Immunotherapymentioning

confidence: 99%

Immunotherapy for the Treatment of Glioblastoma

Thomas¹,

Ernstoff²,

Fadul³

2012

The Cancer Journal

View full text Add to dashboard Cite

Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.

show abstract

Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas

Cited by 25 publications

References 34 publications

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege

Immunotherapy for the Treatment of Glioblastoma

Contact Info

Product

Resources

About